leadf
logo-loader
viewOpen Orphan PLC

Venn Life Sciences launches £4.5mln share placing to fund life after reverse takeover

The cash will be used to bankroll and grow the enlarged group

'raising capital' graphic
More than 80mln shares will be sold at 5.6p each in the City fundraiser arranged by Arden Partners

Venn Life Sciences Holdings plc (LON:VENN) has unveiled plans to raise £4.5mln via a share placing. The cash will be used to bankroll and grow the enlarged group following the takeover of corporate financier Cathal Friel’s latest venture, a firm called Open Orphan.

Friel is reversing the company into Venn in a £5.7mln all-paper deal to bring to the market his platform that helps pharma companies commercialise their products in Europe.

WATCH: Venn Life Sciences to put Open Orphan merger to shareholders next Thursday

"The placing will allow the new management team, who have a strong track record, to realise the full potential of the enlarged group,” the Irish entrepreneur told investors.

“We are excited by the growth potential as we seek to build a leading full-service, Europe wide, high margin consultancy offering services to the fast-growing orphan drug market."

More than 80mln shares will be sold at 5.6p each in the City fundraiser arranged by Arden Partners. Venn Life shares, which had been suspended on AIM, saw trading restored this morning and celebrated with a 107% leap to 5.50p in early deals. 

Friel, a co-founder of Amryt Pharma PLC (LON:AMYT), former chairman of Fastnet Oil & Gas for five years, and now chief executive if Venn, set up Open Orphan two years ago.

Since then more than £2.7mln has been invested into the business, most of which has gone on building a database of all the firms with so-called orphan drugs that treat rare diseases that have either been approved or are currently going through the clinic.

The entrepreneur and his team have also put together a 4,000-strong directory of physicians and key opinion leaders with expertise in marketing and selling orphan drugs.

Normally the drug developers would have to pay a handsome fee to a third-party which would help find those experts, but the company intends to undercut the market with a cheaper annual subscription which gives the companies access to the platform.

At the moment, it is more of a ‘virtual rep’ service, which can be used to support the launch of new products or to promote mature brands.

But Friel and his team want to grow the company into a full-service consultancy for orphan and rare disease drugs.

In a separate announcement, Venn published its results for the year ended December 31. These showed revenues fell sharply to £12.8mln from £15.89mln, resulting in an after-tax loss of £4.3mln.

 -- Adds resoration of trading, share price --

Quick facts: Open Orphan PLC

Price: 18.499 GBX

AIM:ORPH
Market: AIM
Market Cap: £123.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan: New deal with top-three pharma company is 'evidence validation...

Proactive Research analyst Emma Ulker says the news this morning that Open Orphan PLC (LON:ORPH) subsidiary hVIVO has signed a £4mln contract with an unnamed top-three global pharma company is evidence that the validation is building as well as recognition amongst larger players in the industry....

on 08/10/2020

3 min read